

THE BRITISH JOURNAL OF PSYCHIATRY

Volume 144

Published monthly

FEBRUARY 1984

Founded in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science*
from 1855 to 1963.

EDITOR

Hugh Freeman

ASSOCIATE EDITORS

Martin Roth Kenneth Rawnsley

ASSISTANT EDITORS

Sidney Crown
John Cutting
Gaius Davies
Alan Kerr

Margaret Little
Julian Leff
Henry Rollin
Andrew C. Smith

Philip Snaith
William Spry
Peter Tyrer
Gregor Wilkinson

EDITORIAL MANAGEMENT

Jacqueline Yates

ASSISTANT FOR THE BULLETIN

Alison Campbell

Correspondence, manuscripts, books for review, for both the *Journal* and the *Bulletin* should be addressed to the Editor, 17 Belgrave Square, London SW1X 8PG (Tel 01-235 8857). See inside front cover for further instructions.

Advertising enquiries, correspondence and copy should be addressed to Mr. Peter T. Mell, Advertisement Manager, PTM Professional Publications Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (Tel 01-642 0162 PBX).

Subscriptions for non-members of the College are payable directly to the printers, Headley Brothers Ltd, to whom all queries about missing or faulty copies should be addressed within six months of publication and who also supply on order Special Publications and Gaskell Books.

Annual subscription rates 1984 (12 issues post free)

Inland: Institutions £65.00; Individuals £55.00

Overseas: Institutions £90.00, US\$200.00; Individuals £75.00, US\$165.00

Single copies of the Journal, £6.00, US\$12.00 (post free).

Bargain: Special American private subscription \$45.00 for 12 issues post free, to personal subscribers affirming the Journal is for their own use and naming the institution to which they belong and which already subscribes at the institutional rate. For residents of North America only.

USA Mailing Agents, Expeditors of the Printed Word Ltd., 527 Madison Avenue, Suite 1217, New York, NY 10022. 2nd Class postage paid at New York City, NY. (USPS No. 536-870).

Back issues published in 1983 may be purchased from Headley Brothers Ltd and all previous issues from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent, England (Tel 0303 57421).

Printed by Headley Brothers Ltd, Ashford, Kent TN24 8HH, England (Tel 0233 23131).

© 1984 THE ROYAL COLLEGE OF PSYCHIATRISTS

THE UNIVERSITY OF NEWCASTLE
New South Wales

**LECTURER/SENIOR LECTURER IN
PSYCHIATRY**
FACULTY OF MEDICINE

The undergraduate curriculum at Newcastle is fully integrated, problem-based and organized around small groups and individual learning. The Faculty has a community orientation in its education, research and service activities. There is a postgraduate training programme for the RANZCP in which members of the Discipline of Psychiatry are expected to play an active role.

Research interests in the Discipline include preventive psychiatric programmes for adolescents, mother-child relationships and alcoholism. Interdisciplinary research is also encouraged.

Applicants should have a strong commitment to medical education at both undergraduate and postgraduate levels. Research interests in consultation/liaison, community, preventive or other defined areas of psychiatry would be favourably regarded.

Comencing salary is within the range: Senior Lecturer \$A31,390-\$A36,585 per annum, Lecturer \$A23,394-\$A30,734 per annum, depending upon qualifications and experience. A clinical loading of up to \$A8,760 per annum depending on the degree of clinical responsibility may be paid. There is a limited right of private practice. Further information may be obtained from Professor Beverley Raphael, Faculty of Medicine, University of Newcastle.

Applications Close *29 February 1984*.

GENERAL INFORMATION: Conditions of employment, method of application and other particulars, may be obtained from the Association of Commonwealth Universities (Apts), 36 Gordon Square, London WC1H 0PF. Equality of employment opportunity is University policy.

THE TAVISTOCK CLINIC

**Advanced Training in Family
Therapy 1984/85/86**

Applications are invited for a multi-disciplinary clinical training in family therapy for experienced clinicians who are currently engaged in family therapy, who wish to develop their practice and who plan to promote supervision and training schemes within their own agencies.

A two year, one to two day per week programme will include clinical work with families in the Department for Children and Parents with group supervision using video tapes and one-way mirror observation, together with theoretical and experiential seminars, in a variety of approaches. There will be opportunities for members to undertake supervised teaching practice.

A third year of one-day per week is available for selected candidates to specialise in developing their supervisory skills.

Closing date: 17th March 1984

Further details are available from: The Training Administrator, The Tavistock Clinic, 120 Belsize Lane, London NW3 5BA. Telephone: 01-435 7111 ext 469 or 313.

Depression A Constant Source of Anxiety




PROTHIADEN A Consistent Source of Effective Treatment

Prothiaden is an efficient, well tolerated antidepressant with a significant anxiolytic action. It achieves consistently good results in a wide variety of depressive states — including those with associated anxiety — and in patients of all ages. Which is why Prothiaden is now the most widely prescribed antidepressant in the United Kingdom.

Prescribing Information

Presentation: Prothiaden is Dothiepin Hydrochloride B.P., an antidepressant of the tricyclic group. It is available as 25mg capsules and 75mg tablets. **Uses:** Prothiaden is indicated in the treatment of depression and associated anxiety. **Dosage:** Prothiaden should be given in a dosage of 75 to 150mg daily, based on response and severity. This may be taken as a single evening dose. In certain circumstances, i.e. in hospital use, Prothiaden has been given in dosages up to 225mg daily. Elderly — half the normal adult dose may be sufficient. **Precautions and Contra-indications:** Prothiaden has anticholinergic properties; therefore, it may precipitate urinary retention in susceptible individuals and its use should be avoided in patients with existing or potential urinary retention. Prothiaden should not be used in patients with closed-angle glaucoma. Caution is advised when treating epileptic patients and those with cardiovascular disorders. Prothiaden should not be used with MAO inhibitors nor within 14 days of ceasing such treatment. It may modify the action of some CNS depressants, sympathomimetics and hypotensive agents. **Side Effects:** These are usually mild and normally controlled by reducing the dosage. The following have been reported: dryness of mouth, constipation, disturbed accommodation, orthostatic hypotension, palpitations, somnolence, tremor, headache. **Base N.B.S. Price:** 28 x 75mg £2.61. **Product Licence Numbers:** PL0014/5941, PL0014/0209.

 The Boots Company PLC, Nottingham, England. Further information available on request.

PROTHIADEN
Dothiepin Hydrochloride B.P.

The Dependable Antidepressant

Lundbeck Ltd
Lundbeck House
Hastings Street
Luton LU1 5BE



The formula
for successful rehabilitation...
...you together with

Depixol[®]
cis(Z)-flupenthixol decanoate



Helping you to care;
helping them to cope

Depixol Injection and Depixol-Conc. Injection Contains cis(Z)-flupenthixol decanoate, 20mg per ml and 100mg per ml respectively, in thin vegetable oil. **Indications** Psychoses, especially schizophrenia, particularly where there are associated features of withdrawal, inertia or apathy. **Dosage and Administration** By deep intramuscular injection, 1-2ml every 2-4 weeks, to a maximum of 400mg weekly. **Children** Not recommended for children. **Side Effects** Early (frequent) and late (rare) dyskinesias. Extrapyramidal effects sometimes require dose reduction or anti-Parkinson drug treatment. **Contra-indications** Not recommended for overactive patients, or for those with Parkinsonism, severe arteriosclerosis, senile confusional, or advanced renal, hepatic, or cardiovascular disease, intolerance to other neuroleptics, pregnancy. **Package Quantities** Boxes of 10 x 20mg (1ml), 10 x 40mg (2ml), 10 x 100mg (1ml) ampoules; 10 x 20mg and 10 x 40mg syringes; 1 x 200mg (10ml) and 1 x 500mg (5ml) vials. **Further Information** Overdosage should be treated: (a) By anticholinergic anti-Parkinson drugs if extrapyramidal symptoms occur. (b) By sedation (with benzodiazepines) in the unlikely event of agitation or excitement. (c) By noradrenaline in saline intravenous drip if the patient is shocked. **Basic NHS Cost** 10 x 20mg amps £15.53; 10 x 40mg amps £25.99; 10 x 100mg amps £59.53; 10 x 20mg syringes £16.50; 10 x 40mg syringes £26.98; 200mg (10ml) vial £14.74; 500mg (5ml) vial £28.27. (Prices correct at time of printing.)
PL No 0458/007/008 PA Nos 115/1/1,2,3,5,6.

NEW HOPE FOR SCHIZOPHRENICS

New 'Dolmatil'

'Dolmatil' is a totally new type of oral neuroleptic effective in both acute and chronic schizophrenia.

Acute and Chronic Schizophrenia

Dose manipulation is the key to the broad range of efficacy. In doses less than 400mg twice daily 'Dolmatil' tends to alert the chronic patient whose symptoms are mainly negative. In higher doses, ie 400mg-1200mg twice daily; 'Dolmatil' effectively controls the patient with symptoms of delusions and hallucinations, formal thought disorder and incongruity of affect.


Specific Dopamine Antagonist

A specific dopamine antagonist, 'Dolmatil' has been shown not to interfere with other neurotransmitter systems. This is the probable basis of the improved side effect profile of 'Dolmatil' compared to conventional neuroleptics.

Low Incidence of side effects

Very low incidences of tardive dyskinesia and sedation are characteristic of 'Dolmatil.' Moreover, 'Dolmatil' has no significant anti-cholinergic or cardiovascular activity.

^{sulpiride}
Dolmatil
SPECIFIC DOPAMINE ANTAGONIST



PRESCRIBING INFORMATION

Dolmatil Tablets: Plain white round tablets with a transverse breaking line on one side and the mark D200 on the other. Each tablet contains 200mg sulpiride

Indications: Acute and chronic schizophrenia

Dosage: A starting dose of 400mg to 800mg daily, given as one or two tablets twice daily (morning and early evening) is recommended.

Predominantly positive symptoms: Starting dose of at least 400mg twice daily, increasing if necessary up to 1200mg twice daily

Predominantly negative symptoms: Starting dose of 400mg twice daily reducing as required towards 200mg twice daily

Mixed positive and negative symptoms: 400mg - 600mg twice daily. The same dose ranges may be required in the elderly, but should be reduced if there is evidence of renal impairment. Clinical experience in children under 14 years of age is insufficient to permit specific recommendations

Contraindications: Pheochromocytoma

Warnings: Extrapyramidal reactions, principally akathisia have been reported in a small number of cases. If warranted, reduction in dosage or anti-Parkinsonian medication may be necessary. After over a decade of widespread use in many countries, tardive dyskinesia has occurred rarely. Insomnia has been reported. Increased motor agitation has been reported at high dosage in a small number of patients in aggressive, agitated or excited phases of the disease process. 'Dolmatil' may aggravate symptoms. Care should be exercised where hypomania is present. Galactorrhoea, amenorrhoea and gynaecomastia may occur in association with hyperprolactinaemia


Precautions: Epilepsy - anticonvulsant therapy should be continued unchanged. Impaired renal function, as sulpiride is eliminated via the kidney. Pregnancy - the general principle of avoiding drug treatment during pregnancy, particularly during the first sixteen weeks, should be followed

Product Licence Number: PL 5299-0006 **Legal category:** POM **Basic NHS cost:** 63p per day at dose of 600mg daily

Name and address of Distributor: E R Squibb & Sons Ltd, Squibb House, 141-149 Staines Road, Hounslow, Middlesex TW3 3JA


***Trade Marks of E R Squibb & Sons Ltd (Distributor):** DOLMATIL - Trade Mark of SESIF. Authorised User Delagrangue Ltd





The long...

...and the short of it



New Clopixol® Tablets bring an added degree of flexibility to the treatment of psychoses. They are indicated for the treatment of acute psychotic episodes where the rapid control of disruptive symptoms (agitation, suspicion, hostility) is required, and also for the maintenance treatment of chronic schizophrenia where depot injection therapy is refused or unsuitable.

- Rapid control of disruptive symptoms – peak serum levels attained within 4 hours.¹
- Profound antipsychotic effect.^{2,3,4}
- More effective than haloperidol in chronic schizophrenia.²
- Generally fewer side-effects than the phenothiazines.
- Smooth transfer from Clopixol Tablets to Clopixol Injection.

NEW

CLOPIXOL® TABLETS



References

1. Aaes-Jorgensen T. Acta Psychiat Scand 1981; 64: Suppl 294: 64. 2. Heikkila L et al. Acta Psychiat Scand 1981; 64: Suppl 294: 30. 3. Sechter D et al. Acta Psychiat Scand 1981; 64: Suppl 294: 20-24. 4. Graven A, Bugge A. Acta Psychiat Scand 1981; 64: Suppl 294: 13-19.

Prescribing Information

Clopixol Tablets (cis(Z)-clopenthixol dihydrochloride). **Indications** Psychoses, especially in patients who are agitated, aggressive or hostile. **Dosage and Administration: Adults** The usual initial dose is 20-30 mg/day, increasing as necessary to a maximum of 150 mg/day, in divided doses. The usual maintenance dose in chronic schizophrenia is 20-30 mg/day in divided doses. **Children** Not recommended. **Side-effects** Extrapyramidal side-effects may occur and sometimes may require control by anti-Parkinson drugs. **Contraindications** Acute alcohol, barbiturate or opiate poisoning. Intolerance to other neuroleptics. Pregnancy (relative). Use with caution in patients with Parkinsonism, severe arteriosclerosis, senile confusional states; serious renal, hepatic or cardiovascular disease. **Overdosage** Overdosage should be treated by gastric lavage. **Package Quantities and NHS Price (September 1982)** Bottles of 100 Clopixol Tablets 10 mg £7.50. Bottles of 100 Clopixol Tablets 25 mg £15.00. PL No. 0458/0028, 0029. PA No. 115/5/3,4.

Further information and data sheet available from: - Lundbeck Limited, Lundbeck House, Hastings Street, Luton, Beds. LU1 5BE. Tel. Luton 416565.



THINK FIRST, THINK...

MODECATE



MODECATE

Indications. Treatment of psychotic disorders. Dosage — Modecate injection 25mg/ml. Most patients are successfully maintained within the dosage range 12.5mg (0.5 ml) every five weeks to 100 mg (4ml) every two weeks. For full dosage information see Data Sheet. Modecate concentrate injection 100 mg/ml. Adult patients found to require larger volumes of Modecate 25 mg/ml may be transferred directly to the equivalent dose of Modecate concentrate on the basis that 1ml Modecate concentrate is equivalent to 4ml Modecate. Contra-Indications. Patients with marked cerebral atherosclerosis, photochromocytoma, renal or liver failure, or severe cardiac insufficiency. Precautions. Care should be taken in patients,



particularly the elderly, who exhibit marked extrapyramidal reactions to oral phenothiazines. Side effects. Mainly extrapyramidal reactions. Drowsiness, lethargy, dryness of the mouth and mild hypotension may occur. Product Licence No's and Prices. Modecate injection 25 mg/ml. PL 0034/5046. 10 x 1ml ampoules £23.20. Modecate concentrate injection 100 mg/ml. PL 0034/0189. 10 x 0.5ml ampoules £49.99. 5 x 1.0ml ampoules £48.86. Modecate is a Trade Mark of E R Squibb & Sons Ltd. Further information available from: Technical Services Department, E R Squibb & Sons Ltd, 141-149 Staines Road, Hounslow, Middlesex TW3 3JA. Tel 01-572 7422.



First and foremost depot neuroleptic

CLOPIXOL[®] INJ.

(cis(Z)-clopenthixol decanoate 200mg/ml)

**THE MAINTENANCE
TREATMENT
OF PSYCHOSIS**



LUNDBECK NEUROLEPTICS

A DIFFICULT ACT TO FOLLOW



Further information and data sheets available from:
Lundbeck Limited, Lundbeck House, Hastings Street, Luton, Beds. LU1 5BE.

*Trade Mark.

Australia
Royal Children's Hospital/
University of Melbourne

Director

Department of Child and Family Psychiatry,
Royal Children's Hospital and Professorial
Associate (with title of Professor),
The University of Melbourne

Applications are invited for the position of Director, Department of Child and Family Psychiatry at the Royal Children's Hospital, Melbourne. An appointee with an appropriate academic background will be offered by the University of Melbourne the position of Professorial Associate with the title of Professor. The post is a full-time salaried position and the appointee will be selected jointly by the Royal Children's Hospital and the University of Melbourne.

Applicants should hold a medical degree registrable in the State of Victoria and be a member of the Royal Australian and New Zealand College of Psychiatrists or its equivalent. They should have had training in child psychiatry together with extensive clinical, teaching and research experience.

The position of Professor/Director is a new one and will provide the opportunity for the successful applicant to initiate major developments in child psychiatry within the Hospital and the community and to participate in teaching and research.

The Royal Children's Hospital is the paediatric teaching hospital of the University of Melbourne and is the major paediatric centre for South-Eastern Australia servicing a total population of approximately 4.5 million. It is located in Melbourne, a city of 3 million people.

Salary and conditions of service will be in accordance with the Hospitals Remuneration Tribunal at a rate of Specialist Class 4, currently set at \$A57,340 per annum. An on-call allowance of 10 per cent is also applicable, and the successful applicant will be eligible to participate in departmental private practice arrangements. Assistance with re-location expenses will be available.

Enquiries may be directed to Professor Peter Phelan, Professor of Paediatrics, or the undersigned. Further details of the position and application procedures may be obtained from the Chief Executive's Office. Applications should be addressed to the undersigned and close by Friday, February 24th, 1984. The Hospital reserves the right to accept late applications or to make an appointment by invitation.

Dr. Barry R. Catchlove,
Chief Executive,

**Royal Children's
Hospital**

Flemington Road, Parkville, Victoria 3052, Australia.

A Manitoba Opportunity...

PSYCHIATRISTS

BRANDON AND SELKIRK MENTA,
HEALTH CENTRES, MANITOBA
CANADA

Up to \$67,338 plus \$5,000 qualification
pay dependent on qualifications and
experience

Duties: Challenging career opportunities for Psychiatrists are available in our provincial mental health centres at Brandon and Selkirk. We require creative, innovative individuals to work with a community-orientated, multi-disciplinary team to provide an eclectic approach to in-hospital and community-based mental health services, including adult and children services, travelling clinics and day-care facilities.

QUALIFICATIONS: Canadian Certification in Psychiatry, or eligibility for Canadian Certification. Applicants must be eligible for full registration with the College of Physicians and Surgeons of Manitoba.

COMPETITION NO. 370

CLOSING DATE: As soon as possible

Please forward completed Civil Service application, quoting competition number, directly to:

Personnel Management Services
Department of Health
602-330 Graham Avenue
Winnipeg, Manitoba
R3C 4A5

MANIT^{BA}

AN EQUAL OPPORTUNITY EMPLOYER

CAPE BRETON HOSPITAL/BRAEMORE HOME CORPORATION

PSYCHIATRIST

(GENERAL AND CHILD PSYCHIATRY)

The Cape Breton Hospital invites applications for a full-time position of General and Child Psychiatrist. The hospital is a 60-bed (30-bed multi-treatment unit; 18-bed long term care; 12-bed observation/admission unit), as well, the hospital operates a day centre (partial hospitalization) and an expanding community mental health program.

The successful applicant will be a specialist psychiatrist with Canadian Certification or Fellowship and a license to practise in Nova Scotia (L.M.C.C. or N.B. ME, (U.S.) and a current license to practise in an American state).

A one year (renewable) temporary Nova Scotia license is available for candidates who possess Canadian certification and are eligible to write for L.M.C.C.

BENEFITS:

- EXCELLENT SALARY/OTHER BENEFITS PLANS;
- PRIVATE PRACTISE (WITH CERTAIN LIMITATIONS) FOR SALARIED POSITIONS (WITH FULL LICENSE);
- UP TO \$3,000 MOVING EXPENSE ALLOWANCE;
- RELOCATION GRANT OF \$5,000 AFTER ONE YEAR SERVICE;
- AN ADDITIONAL \$10,000/YEAR OVER SALARY FOR TWO (2) YEARS.


APPLICATIONS INCLUDING FULL CURRICULUM VITAE AND THE NAMES AND ADDRESSES OF THREE (3) REFERENCES MAY BE FORWARDED TO:

JIM HUNTER, DIRECTOR OF PERSONNEL, P.O. BOX 515, SYDNEY, N.S. B1P 6H4

**PRIVATE
PSYCHIATRIC TREATMENT**

**Your Patient –
a problem with drink?
Consider St. Andrew's.**

For details: The Medical Director, FREEPOST
St. Andrew's Hospital, Northampton NN1 5DG
Telephone Northampton (0604) 29696

St. Andrew's Hospital 

Revised Edition

Controlled Drinking

NICK HEATHER
and IAN ROBERTSON

with a foreword by D. L. DAVIES

'The belief that abstinence is the only cure for alcoholism is widely accepted in both medical and public opinion. The authors of *Controlled Drinking* contend that this belief is not supported by scientific evidence... As the authors are clinical psychologists they champion an approach to treatment that is rooted in behavioural and educational techniques.'

British Medical Journal

328 pages

Paperback 0 416 36460 8

£6.95

METHUEN

11 New Fetter Lane, London EC4P 4EE